We are live on
!
Find out more
AA
AlphaCentric Advisors Portfolio holdings
AUM
$100M
This Fund
S&P 500
This Quarter
Est. Return
-2.91%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$136M
AUM Growth
-$30M
(-18%)
Cap. Flow
-$21.6M
Cap. Flow
% of AUM
-15.92%
Top 10 Holdings %
Top 10 Hldgs %
25.49%
Holding
262
New
34
Increased
55
Reduced
87
Closed
45
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Enovis
ENOV
|
+$1.04M |
| 2 |
Amphastar Pharmaceuticals
AMPH
|
+$1.04M |
| 3 |
Invesco QQQ Trust
QQQ
|
+$958K |
| 4 |
Invesco NASDAQ 100 ETF
QQQM
|
+$955K |
| 5 |
Sarepta Therapeutics
SRPT
|
+$929K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UroGen Pharma
URGN
|
+$2.16M |
| 2 |
Corcept Therapeutics
CORT
|
+$2.14M |
| 3 |
NARI
Inari Medical, Inc. Common Stock
NARI
|
+$2.13M |
| 4 |
KALV
KalVista Pharmaceuticals
KALV
|
+$1.49M |
| 5 |
Perspective Therapeutics
CATX
|
+$1.35M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 60.25% |
| 2 | Real Estate | 12.98% |
| 3 | Financials | 6.42% |
| 4 | Industrials | 2.59% |
| 5 | Technology | 2.57% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
176
Lennar Class A
LEN
$20B
| $91.1K | 0.07% |
628
-154
| -20% | -$23.4K |
|
177
Chubb
CB
$137B
| $89.5K | 0.07% |
+351
| New | +$90.1K |
|
178
Applovin
APP
$143B
| $83.7K | 0.06% |
+1,006
| New | +$78.1K |
|
179
Celanese
CE
$4.89B
| $82.4K | 0.06% |
611
-22
| -3% | -$3.36K |
|
180
Burlington
BURL
$22.2B
| $81.4K | 0.06% |
+339
| New | +$69.8K |
|
181
Comcast
CMCSA
$84.9B
| $80.8K | 0.06% |
2,064
-66
| -3% | -$2.58K |
|
182
Prudential Financial
PRU
$41B
| $79.8K | 0.06% |
+681
| New | +$78.6K |
|
183
Reinsurance Group of America
RGA
$15.8B
| $79.4K | 0.06% |
+387
| New | +$77.3K |
|
184
First Citizens BancShares
FCNCA
$24.1B
| $79.1K | 0.06% |
47
+1
| +2% | +$1.67K |
|
185
Comfort Systems
FIX
$60.3B
| $78.5K | 0.06% |
+258
| New | +$82K |
|
186
Progressive
PGR
$123B
| $77.5K | 0.06% |
+373
| New | +$78.1K |
|
187
Allstate
ALL
$65.3B
| $77K | 0.06% |
+482
| New | +$80.4K |
|
188
Emcor
EME
$33.1B
| $75.9K | 0.06% |
+208
| New | +$76.7K |
|
189
KKR & Co
KKR
$87.1B
| $74.3K | 0.05% |
+706
| New | +$71.9K |
|
190
Charter Communications
CHTR
$15.9B
| $69.7K | 0.05% |
233
-9
| -4% | -$2.46K |
|
191
MGM Resorts International
MGM
$11.9B
| $69.3K | 0.05% |
1,560
-3,671
| -70% | -$153K |
|
192
Cardinal Health
CAH
$52.9B
| $66.4K | 0.05% |
675
-3,871
| -85% | -$394K |
|
193
Norwegian Cruise Line
NCLH
$8.95B
| $62.1K | 0.05% |
3,304
-4,006
| -55% | -$70.3K |
|
194
GXO Logistics
GXO
$6.07B
| $55.4K | 0.04% |
1,097
+13
| +1% | +$656 |
|
195
Arista Networks
ANET
$213B
| $50.1K | 0.04% |
572
-880
| -61% | -$65.4K |
|
196
Broadcom
AVGO
$1.8T
| $43.3K | 0.03% |
+270
| New | +$37.8K |
|
197
Duolingo
DUOL
$6.24B
| $41.9K | 0.03% |
+201
| New | +$41.2K |
|
198
Super Micro Computer
SMCI
$15.4B
| $41.8K | 0.03% |
+510
| New | +$43.6K |
|
199
Warner Bros
WBD
$64.8B
| $40.8K | 0.03% |
5,487
+66
| +1% | +$529 |
|
200
Elastic
ESTC
$6.52B
| $39.8K | 0.03% |
+349
| New | +$36.7K |
|
Similar funds
WCM
FCM
BIA
AGAM
E
HCM
AC
OIS
AlphaCentric Advisors's Q2 2024 Portfolio in Review
As of Q2 2024, AlphaCentric Advisors held 262 positions worth $136M, down 18% from $166M the previous quarter. Its ten largest holdings account for 25% of the portfolio.
AlphaCentric Advisors withdrew a net $21.6M in Q2 2024, closing 45 positions and reducing 87 holdings. Its most notable exit was UroGen Pharma, an estimated $2.16M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 60% of assets, down from 61% a quarter earlier, followed by Real Estate and Financials.
Against the trend, AlphaCentric Advisors opened a new position in Enovis worth $904K.
- AlphaCentric Advisors's largest Q2 2024 buy was Enovis: 20,000 shares worth $904K.
- AlphaCentric Advisors added most to Invesco QQQ Trust in Q2 2024, an estimated $958K increase.
- AlphaCentric Advisors's biggest Q2 2024 reduction was Inari Medical, Inc. Common Stock, cutting an estimated $2.13M.
- AlphaCentric Advisors fully exited UroGen Pharma in Q2 2024, selling an estimated $2.16M.
- AlphaCentric Advisors's ten largest holdings make up 25% of its $136M portfolio in Q2 2024.
- AlphaCentric Advisors opened 34 new positions and closed 45 in Q2 2024.
- AlphaCentric Advisors's portfolio value fell 18% quarter-over-quarter to $136M.
Based on AlphaCentric Advisors's 13F filing for Q2 2024, filed 25 Jul 2024.